The Mitochondria-Targeted Antioxidant MitoQ Modulates Mitochondrial Function and Endoplasmic Reticulum Stress in Pancreatic β Cells Exposed to Hyperglycaemia

Irene Escribano-Lopez a, Celia Bañuls a, Noelia Diaz-Morales a, Francesca Iannantuoni a, Susana Rovira-Llopis a, Ramon Gomis b, Milagros Rocha c, Antonio Hernandez-Mijares a, d, e, Michael P. Murphy f, Victor M. Victor a, c, g

aService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain, bCiberdem - Department of Endocrinology and Nutrition, Hospital Clinic, School of Medicine, University of Barcelona, Diabetes and Obesity Research Laboratory, Institut d’Investigacions Biomèdiques August Pi i Sunyer (Idibaps), Barcelona, Spain, cCiberehd - Departments of Pharmacology and Physiology, University of Valencia, Valencia, Spain, dInstitute of Health Research INCLIVA, University of Valencia, Valencia, Spain, eDepartment of Medicine, University of Valencia, Valencia, Spain, fMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, United Kingdom, gDepartment of Physiology, University of Valencia, Valencia, Spain

Key Words
Pancreatic β cells • Oxidative stress • Mitochondrial dysfunction • ER stress • Type 2 Diabetes • MitoQ

Abstract
Background/Aims: Mitochondria-targeted antioxidants such as mitoquinone (MitoQ) have demonstrated protective effects against oxidative damage in several diseases. The increase in reactive oxygen species (ROS) production during glucose metabolism in β cells can be exacerbated under hyperglycaemic conditions such as type 2 diabetes (T2D), thus contributing to β cell function impairment. In the present work, we aimed to evaluate the effect of MitoQ on insulin secretion, oxidative stress, endoplasmic reticulum (ER) stress and nuclear factor kappa B (NFκB) signalling in a pancreatic β cell line under normoglycaemic (NG, 11.1 mM glucose), hyperglycaemic (HG, 25 mM glucose) and lipidic (palmitic acid (PA), 0.5mM) conditions.
Methods: We incubated the pancreatic β cell line INS-1E with or without MitoQ (0.5µM) under

I. Escribano-Lopez and C. Bañuls contributed equally to this work.

Victor M. Victor
FISABIO-University Hospital Doctor Peset
Avda Gaspar Aguilar 90, 46017, Valencia (Spain)
Tel. (+34)961622757, Fax (+34)961622492, E-Mail victor.victor@uv.es
NG, HG and PA conditions. We then assessed the following parameters: glucose-induced insulin secretion, O$_2$ consumption (with a Clark-type electrode); mitochondrial function, oxidative stress parameters and calcium levels (by fluorescence microscopy); ER stress markers and NFκB-p65 protein levels (by western blotting). **Results:** MitoQ increased insulin secretion and prevented the enhancement of ROS production and O$_2$ consumption and decrease in GSH levels that are characteristic under HG conditions. MitoQ also reduced protein levels of ER stress markers (GRP78 and P-eIF2α) and the proinflammatory nuclear transcription factor NFκB-p65, both of which increased under HG. MitoQ did not significantly alter ER stress markers under lipidic conditions. **Conclusion:** Our findings suggest that treatment with MitoQ modulates mitochondrial function, which in turn ameliorates endoplasmic reticulum stress and NFκB activation, thereby representing potential benefits for pancreatic β cell function.

**Introduction**

During the onset of type 2 diabetes (T2D), glucose homeostasis is altered due to impairment of the compensatory response of β cells [1]. In addition to the destruction of pancreatic β cells [2, 3], T2D is also associated with oxidative stress and mitochondrial dysfunction [4-6], with mitochondria representing the main source of reactive oxygen species (ROS) in mammalian cells. In this way, the increase in ROS levels in pancreatic β cells under hyperlipidaemia and hyperglycaemia is one of the key events leading to the impairment of β cell function in T2D [7], although the exact underlying mechanisms are yet to be elucidated.

Under normal conditions, pancreatic β cells generate ATP by metabolizing glucose via glycolysis and through the tricarboxylic acid cycle. During this process, ROS are released and counteracted by antioxidant cell defences. Moreover, β cells modulate blood glucose concentration by releasing insulin, which occurs when the enhanced metabolism of glucose in β cells increases the ATP/ADP ratio and leads to a rapid influx of Ca$^{2+}$, which in turn triggers the release of insulin. The hyperglycaemic (HG) conditions typical in T2D patients lead to increased ROS production [8, 9], which can be exacerbated under hyperlipidaemia; oxidation of free fatty acid-derived acetyl CoA by the TCA cycle and β-oxidation are enhanced, which leads once again to increased ROS production [10]. As pancreatic β cells are highly susceptible to oxidative damage [11], antioxidant therapies that improve or avoid oxidative stress may help ameliorate damage.

Oxidative stress has also been related to endoplasmic reticulum (ER) stress under insulin resistance conditions [12]. In fact, ER stress plays an important role in β cell impairment under both hyperlipidaemic and hyperglycaemic conditions [13, 14], and constitutes a key mediator of β cell apoptosis [15]. Furthermore, it has been reported that ER stress signalling might be triggered by oxidized LDL through the induction of P-eIF2α, ATF6 and IRE1α in vascular cells [16]. In addition, oxidative stress can activate NFκB, leading to changes in proinflammatory gene expression, eventually inducing cardiovascular impairment [17].

Therefore, therapies that decrease mitochondrial impairment, oxidative stress and, consequently, ER stress may be effective in the treatment of T2D and its deleterious effects [4]. For this reason, mitochondria-targeted antioxidants are emerging as potential protective therapies against oxidative damage in cardiovascular diseases, T2D and other conditions [18, 19]. The most widely used mitochondria-targeted antioxidant is mitoquinone (MitoQ), an ubiquinone derivate that specifically targets mitochondria by covalent attachment to a lipophilic triphenylphosphonium (TPP) cation [20, 21] and which can prevent lipid peroxidation. Due to the mitochondrial membrane potential (ΔΨm), this cation is accumulated within mitochondria inside the cells.

Therefore, the aim of the current study was to evaluate the extent of the potentially beneficial effects of the mitochondria-targeted antioxidant MitoQ on insulin secretion, oxidative stress, ER stress and NFκB in the pancreatic β cell line INS-1E - a widely used β-cell surrogate - under normoglycaemic (NG), HG and lipidic conditions.
**Materials and Methods**

**Cell culture and treatments**

The pancreatic β cell line INS-1E was cultured in a humidified chamber with 5% CO₂ in RPMI-1640 medium (Biowest, Nuaille, France) at 11.1 mM glucose supplemented with 5% (vol./vol.), heat-inactivated foetal calf serum (FCS), 10 mM HEPES, 2mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM sodium pyruvate and 50 μM β-mercaptoethanol, as previously described [22]. All experiments were performed in cells from passages 40-50. After 4 days of pre-culture in a T75 flask, cells were transferred to T25 flasks or well plates and maintained a further 2 days at 11.1 mM glucose (NG) or exposed to one of the following conditions for 24 hours: high glucose concentration (25 mM, HG) [23] or 0.5 mM palmitate-BSA conjugate [24]. Upon 85% confluency, cells were treated for 3 or 24 hours with 0.5 µM MitoQ or decyl-TPP in order to evaluate the non-specific effects of MitoQ. Decyl-TPP is similar in hydrophobicity to MitoQ but without the ubiquinol antioxidant moiety [25].

**Cell viability assay**

Cell viability was assessed using the colorimetric MTT assay Kit (Roche Molecular Biochemicals, Mannheim, Germany) after several periods (from 1h to 24 h) of treatment with the mitochondria-targeted antioxidant and decyl-TPP. This colorimetric assay measures the activity of enzymes that reduce 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a yellow tetrazole, to a purple formazan dye. Absorbance of dissolved formazan crystals was measured in a microplate spectrophotometer reader at 570 nm. Data are displayed as a percentage of absorbance relative to that of the untreated cells.

**Glucose-induced insulin secretion (GIIS)**

INS-1E β cells were seeded at a density of 0.5×10⁶ cells/well in a 24-well plate. Glucose-stimulated secretion was performed after 2 days of culture in RPMI growth medium in the presence or absence of PA 0.5mM (24h). During the last 3h, cells were exposed to 0.5µM MitoQ and then washed twice with Hanks’ balanced salt solution (HBSS, Sigma Aldrich, Missouri, US). As a basal insulin secretion level, we used HBSS supplemented with 3mM glucose; and as a stimulated level we used HBSS supplemented with 15 mM glucose. The supernatants were then stored for subsequent determination of insulin levels using a rat insulin ELISA kit (Mercodia AB, Uppsala, Sweden). The inter- and intra-assay coefficients of variation were all under 10%. Insulin secretion was normalized to total cellular protein.

**Measurement of O₂ consumption**

INS-1E β cells were detached by trypsinization, counted with a Scepter 2.0 cell counter (Millipore Iberica, Madrid, Spain), resuspended (5×10⁶ cells/mL) in HBSS and placed in a gas-tight chamber. Mitochondrial O₂ consumption was then measured with a Clark-type O₂ electrode (Rank Brothers, Bottisham, U.K.) [26]. An inhibitor of the electron transport chain, sodium cyanide (10⁻³ mol/L), was used to confirm that O₂ consumption was mainly mitochondrial (95-99%).

**Membrane potential (ΔΨm), ROS production, glutathione (GSH) and calcium levels measurement**

Fluorescence probes tetramethylrhodamine methylester (TMRM; 5×10⁻⁶ mol/l), MitoSOX (5×10⁻⁶ mol/l), 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA; 5×10⁻⁶ mol/l), 5-chloromethylfluorescein diacetate (CMFDA; 1×10⁻⁶ mol/l), and (acetoxyl)ethyl ester (Fluo-4 AM; 1×10⁻⁶ mol/l) were employed to estimate ΔΨm, mitochondrial ROS, total ROS, GSH content and calcium levels, respectively. For these measurements, cells were seeded in 48-well plates and incubated for 30 min with the respective fluorescent probe. Fluorescence was then measured by fluorometry using a fluorescence microscope (IX81; Olympus) coupled to the static cytometry software “ScanR” (Olympus). Nuclei were visualized with Hoechst 33342. Measures of fluorescence are expressed in arbitrary units. Experiments were performed in triplicate and 16 images per well were recorded and analysed. All fluorochromes were purchased from Thermo Fisher Scientific, Waltham, US.

**Western blotting (WB)**
Following the previously described treatments, total protein extracts from INS-1E β cells were obtained by lysing on ice for 15 min with an extraction buffer (400 mM NaCl, 20 mM HEPES pH 7.5, 20% Glycerol, 0.1 mM EDTA, 10 μM Na2MoO4 and 0.5%, and Nonidet P-40) containing protease inhibitor mixture (10 mM NaF, 1 mM Na3VO4, 10 mM PNP, and 10 mM β-glycerolphosphate) and dithiothreitol 1mM, and by performing centrifugation at 4°C for 15 min. Concentration of the isolated supernatant-containing protein extract was determined using the BCA protein assay kit (Thermo Fisher Scientific, IL, US). Twenty-five micrograms of protein were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes. After blocking, membranes were incubated overnight at 4°C with the following primary antibodies: anti-GRP78 rabbit polyclonal antibody (Abcam, Cambridge, MA), anti-P-eIF2α-pS52 rabbit polyclonal antibody (Life Technologies, California, US), anti-NFκB-p65 (phospho S536) rabbit polyclonal antibody (Abcam, Cambridge, MA) and anti-actin rabbit polyclonal antibody (Sigma Aldrich, Missouri, US). Blots were incubated with the secondary antibody HRP goat anti-rabbit (Millipore Iberica, Madrid, Spain) and developed for 2 min with ECL plus reagent (GE Healthcare, LC, UK) or Supersignal West Femto (Thermo Fisher Scientific, IL, US). The protein signal was detected by chemiluminescence and visualized in a Fusion FX5 acquisition system (Vilbert Lourmat, Marne La Vallée, France). Images were analysed and quantified by densitometry using Bio1D software (Vilbert Lourmat, Marne La Vallée, France) and protein bands were normalized to the expression of actin in the same sample.

**Statistical analysis**

Data analysis was performed with SPSS 17.0. Bar graphs show mean ± SEM. Data were compared with a one-way analysis of variance (ANOVA) followed by Student-Newman-Keuls post-hoc test. Significant differences were considered when p<0.05.

**Results**

**Cell Viability**

The cell viability of MitoQ at 0.5μM was similar between 1 and 24h of exposure with respect to untreated cells. However, surprisingly, dTPP showed a significant decrease in cell viability at 10 and 24h, as shown in Supplementary Fig. 1 (all supplementary material available online at www.cellphysiolbiochem.com).

**Glucose-induced insulin secretion (GIIS)**

Stimulation with 15mM glucose plus treatment with MitoQ significantly increased insulin secretion with respect to stimulation with 3mM glucose under normo-lipidic conditions (Fig. 1). This incremental effect of 15 versus 3 mM glucose was 86.7% when mitoQ was present versus 20.5% in control conditions. In contrast, there were no significant differences in insulin secretion in the lipidic environment.

In addition, in the normo-lipidic environment there was a trend toward a greater release of insulin at 15 mM glucose in the mitoQ versus control group (p=0.115).

**Mitochondrial Function**

An O2 electrode was used to monitor the rate of O2 consumption in INS-1E β cells treated with and without MitoQ. O2 consumption by the cells was mainly mitochondrial, since addition of sodium cyanide resulted in almost complete (95-99%) inhibition of O2.
consumption (not shown). Rates of \(O_2\) consumption in \(\beta\) cells, whether treated or not with MitoQ, remained constant under NG. Interestingly, although HG enhanced \(O_2\) consumption rates \((p<0.05)\), MitoQ-treated \(\beta\) cells showed a downward trend under these conditions (Fig. 2A and 2B). In the lipidic environment, the response of MitoQ to \(O_2\) consumption was attenuated with respect to the HG condition, although there was a trend towards an improvement \((p=0.100)\) when we compared the PA condition without vs with MitoQ for 3h. These results did not change when cells were exposed to MitoQ for 24h (Supplementary Fig. 2A). Similarly, no changes were observed with respect to \(\Delta\Psi_m\), measured as TMRM fluorescence, in any of the conditions studied (Fig. 2C).

INS-1E \(\beta\) cells exhibited higher levels of MitoSOX oxidation under HG than under NG conditions, which was consistent with an increase in mitochondrial ROS production; however, MitoQ decreased MitoSOX oxidation specifically in cells cultured under HG conditions (Fig. 2D, \(p<0.01\)).

None of these oxidative stress parameters was affected by treatment with the control compound decyl-TPP, which has the same mitochondrial-targeting moiety as MitoQ, but lacks an antioxidant effect.

**Oxidative stress parameters**

Total ROS fluorescence, evaluated by DCFH-DA fluorescence, was significantly higher in untreated cells under HG with respect to NG \((p<0.05)\). Interestingly, MitoQ treatment decreased total ROS \((p<0.05)\) to values similar to those observed under NG conditions, thus revealing a decrease in oxidative stress under HG. MitoQ did not alter total ROS in INS-1E \(\beta\) cells under NG (Fig. 3A).

On the other hand, CMFDA fluorescence, which is proportional to the content of the free thiol form of GSH in INS-1E \(\beta\) cells, decreased under HG \((p<0.05)\) and was restored in the presence of MitoQ \((p<0.05)\), suggesting a protective role. MitoQ did not alter the levels of GSH in NG conditions (Fig. 3B).

These results demonstrate that HG conditions induce oxidative stress in INS-1E \(\beta\) cells and that MitoQ prevents this effect by reducing levels of ROS and preserving antioxidant content. We can also confirm that none of the oxidative stress parameters was affected by treatment with the control compound decyl-TPP.
**ER stress**

As oxidative stress is closely related to ER stress, we investigated whether the unfolded protein response (UPR) was activated in INS-1E β-cells by assessing protein levels of the ER stress markers GRP78 and P-eIF2α.

INS-1E β cells cultured under HG displayed enhanced protein levels of the glucose-regulated protein 78 (GRP78) chaperone (Fig. 4A) and phosphorylated eukaryotic translation initiation factor 2 alpha (P-eIFα, Fig. 4B) with respect to control cells (p<0.01), which pointed to activation of the UPR. These effects under HG conditions were reversed by addition of MitoQ (p<0.01, Fig. 4A and 4B), which did not modify protein levels in NG or PA conditions. However, although there was no significant difference in GRP78 in the lipidic condition, there was a trend (p=0.147) towards a decrease when cells were exposed...
to MitoQ. No changes were observed with respect to ER stress markers after 24h exposure to MitoQ in any of the conditions studied (Supplementary Fig. 2B and 2C).

Fluo4-AM fluorescence, employed to measure calcium content, followed a similar pattern to that of ER stress proteins. Whereas calcium levels remained constant in INS-1E β cells with or without MitoQ under NG conditions, there was an increase in intracellular calcium levels in the HG condition that was reverted in the presence of MitoQ, suggesting a preventive effect (Fig. 4C). Decyl-TPP treatment did not affect any of these parameters.

**Levels of NFκB-p65 (phospho S536)**

INS-1E β cells showed an increase in NFκB-p65 levels (Fig. 5, p<0.01) under HG conditions, but MitoQ treatment returned NFκB-p65 protein levels to those observed under NG conditions (Fig. 5, p<0.01), thus suggesting an anti-inflammatory effect. MitoQ did not modify NFκB-p65 levels under NG or PA conditions. Decyl-TPP treatment did not affect NFκB-p65 protein expression. No changes were observed with respect to NFκB after 24h exposure to MitoQ (Supplementary Fig. 2D).

**Discussion**

In the present study we demonstrate that HG induces an increase of mitochondrial oxygen consumption, mitochondrial ROS production, the ER stress markers GRP78 and P-eIF2α, calcium levels and NFκB-p65 protein expression in pancreatic β cells, while HG, in contrast, decreases GSH levels in said cells. In addition, we demonstrate the potential beneficial effects of the mitochondrial antioxidant MitoQ, which appears to restore conditions after its administration.

INS-1E is a cell line that displays stable glucose responsiveness and closely mimics the function of normal pancreatic islets. In addition, INS-1E cells are responsive to potentiators of glucose signalling, which makes them useful for studying the mechanisms involved in the regulation of insulin secretion. They are particularly suitable for testing potential therapeutic agents for diabetes treatment, such as mitochondrial-targeted antioxidants [27]. In this sense, our present data demonstrate that MitoQ treatment together with high glucose stimulation significantly increases insulin secretion, suggesting an improvement of β cell function.

HG is closely related to oxidative stress and mitochondrial dysfunction [28, 29]. In fact, we have previously demonstrated that leukocytes from T2D patients present oxidative stress, mitochondrial dysfunction and ER stress [28]. Furthermore, different studies have shown the beneficial effects of mitochondrial antioxidant enzymes under HG, as they protect against oxidative stress [30]. In light of this knowledge, we set out to assess whether mitochondria-targeted antioxidants exert beneficial effects under HG, as previously demonstrated in leukocytes from T2D patients in our laboratory [31]. In fact, MitoQ has been shown to be an effective therapeutic strategy for diabetic nephropathy in the Ins2^−/−Akita mouse model [18], and promotes the survival and function of pancreatic β cells when they are subjected
to glucotoxicity and glucolipotoxicity by improving insulin secretion [32]. In addition to the above, we selected MitoQ for the present study due to its biocompatibility and safety at levels whose efficacy has been demonstrated previously, and again in this work. Previous studies have shown that TPP⁺ compounds, such as MitoQ, when used at typical culture concentrations, can affect mitochondrial function depending on the linker group but not on antioxidant properties [33]. Under our conditions, MitoQ did not disrupt mitochondrial function and the decyl-TPP control compound was not protective. It is important to highlight that MitoQ can concentrate rapidly in mitochondria several 100-fold due to its high membrane potential, which helps to prevent lipid peroxidation. MitoQ does not react with H₂O₂ or organic radicals, but does so with O₂⁻, among other radical oxygen and carbon species. The fact that MitoQ can prevent lipid peroxidation highlights the important role of this compound under oxidative stress conditions [34]. In addition, MitoQ is oriented with the TPP⁺ moiety near the membrane surface, accessing the membrane core to act as a chain-breaking antioxidant and allowing recycling of MitoQ to its ubiquinol form via reduction by complex II [35].

HG and hyperlipidaemia are related to mitochondrial ROS production in pancreatic β cells during T2D [7, 32]. In fact, β cells are particularly susceptible to damage by ROS because of their reduced expression of antioxidant enzymes [36]. In relation to this, the results of the present study show that treatment with MitoQ reduces mitochondrial O₂⁻ consumption under HG conditions, as well as total and mitochondrial ROS, and enhances GSH levels, thus exerting an antioxidant effect. These results are in line with those of previous studies showing that MitoQ reduces ROS and modulates antioxidant activities such as glutathione peroxidase (GPX1) under oxidative stress conditions in propionic acidemia patient-derived fibroblasts [37] and in leukocytes from T2D patients [31]. Moreover, mitochondria-targeted antioxidants have also been shown to maintain mitochondrial morphology, to restore intracellular ATP levels and to increase β cell survival under glucotoxic and glucolipotoxic conditions [32].

It is well known that ER stress and oxidative stress are related [28, 38], which in turn links ER stress to mitochondrial ROS. In this sense, several studies have focused on the contribution of ER stress to the development of insulin resistance and T2D [39, 40]. In this sense, it has been described that autophagy can regulate insulin resistance following ER stress in diabetes [41]. In addition, ER stress has been implicated in apoptosis of pancreatic β cells in a diabetic mouse model [42], and of leukocytes in T2D patients [28, 43]. In addition, Sage et al. [44] showed GRP78, sXBP1 and CHOP levels to be positively correlated with glucose levels in leukocytes from patients with metabolic syndrome. In accordance with these data, our present findings demonstrate that HG enhances levels of ER stress markers such as GRP78 and P-eIF2α, and intracellular calcium levels. Interestingly, MitoQ treatment reversed these effects, suggesting that this molecule ameliorates the mitochondrial disruption which leads to ER stress. Furthermore, under lipidic conditions, levels of GRP78 were increased, although not significantly, while MitoQ partially reversed this effect. In this sense, it has been described that palmitate causes impaired β-oxidation and citric acid cycle flux, suggesting that this undermined mitochondrial metabolism has important implications for metabolic diseases such as type 2 diabetes [45]. In addition, ER stress/UPR activation plays a critical role in lipid metabolism and homeostasis. ER stress-dependent dysregulation of lipid metabolism may lead to dyslipidemia, insulin resistance, cardiovascular disease, type 2 diabetes, and obesity [46].

It is well known that oxidative stress leads to pro-inflammatory responses. Specifically, it has been reported that an increase of ROS production can activate the pro-inflammatory nuclear factor NFκB, thus contributing to insulin resistance [47, 48]. In this sense, we have previously reported a significant increase in NFκB expression in leukocytes of T2D patients [31]. For this reason, we decided to explore whether the antioxidant MitoQ has an effect on p65-NFκB protein expression in pancreatic β cells under HG and lipidic conditions. Although we have assessed the expression of p65 (phospho S563) in total cell protein extracts rather than in nuclear extracts, our results show an increase in the protein NFκB-p65 under HG, which was reverted in the presence of MitoQ. This identifies MitoQ as a mitochondrial
antioxidant capable of modulating, not only oxidative stress and ER stress, but also the inflammatory response. IKK-mediated S536 phosphorylation is critical for activation of the canonical NFκB pathway. In previous research, Day et al. found that IKK-dependent S536 phosphorylation was also required for RelA/p65 nuclear translocation, acetylation in the nucleus, and, thus, NFκB activation induced by HDAC inhibitors [49]. Furthermore, earlier studies have demonstrated that glucose intolerance in obese mice is attenuated after inhibition of the IKKβ/NFκB pathway [50], which suggests this signaling pathway is a central player in the development of T2D. For this reason, we foresee MitoQ treatment as an option for the prevention and/or treatment of insulin resistance and, hence, T2D.

Conclusion

Overall, our findings provide a better understanding of the pathophysiological mechanisms at work in pancreatic β cells under HG. Importantly, our data show that treatment with MitoQ modulates insulin secretion, mitochondrial function, ER stress and the NFκB signalling pathway, suggesting that this compound exerts beneficial effects that can be taken advantage of to improve pancreatic β cell function.

Abbreviations

ΔΨm (mitochondrial membrane potential); CMFDA (5-chloromethylfluorescein diacetate); DCFH-DA (2',7'-dichlorodihydrofluorescein diacetate); ER (endoplasmic reticulum); FCS (fetal calf serum); Fluo-4 (AM, (acetyloxy)me-thyl ester); GIS (Glucose-induced insulin secretion); GRP78 (glucose-regulated protein 78 chaperone); GSH (glutathione); HG (hyperglycaemia); INS-1E (pancreatic β cells isolated from insulinoma; MitoQ, mitoquinone); MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); NFκB (nuclear factor kappa B); NG (normoglycaemia); PA (palmitic acid); P-eIF2α (phosphorylated eukaryotic translation initiation factor 2 alpha); ROS (reactive oxygen species); TMRM (tetramethylrhodamine methylester); T2D (type 2 diabetes); TPP (triphenylphosphonium); UPR (unfolded protein response); WB (western blotting).

Acknowledgements

The authors thank Brian Normanly (University of Valencia/CIBERehd) for his editorial assistance; and Rosa Falcón and Carmen Ramirez (FISABIO) for their technical assistance. This study was financed by grants PI15/1424, PI16/1083, PI16/0301, and CIBERehd CB06/04/0071 by Carlos III Health Institute, PROMETEOII 2014/035 from the Regional Ministry Education of Valencian Community and by the European Regional Development Fund (ERDF ‘A way to build Europe’); UGP15-193 and UGP-15-220 by FISABIO. I.E.-L. is recipient of a predoctoral contract from FISABIO (UGP-15-144). N.D.-M. is a recipient of PFIS contracts from Carlos III Health Institute (FI14/00125). FI is recipient of contract from Generalitat Valenciana GRISOLIAIP/2016/015. S.R.-L. is recipient of a Juan de la Cierva-Formación contract from the Spanish Ministry of Economy and Competitiveness (FJCI-2015-25040). V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CII16/00037, respectively). Work in M.P.M.’s lab is supported by the Medical Research Council UK (MC_U105663142) and by a Wellcome Trust Investigator award (110159/Z/15/Z). Unrestricted grant from Menarini S.A.
Disclosure Statement

The authors declare that no conflicts of interest exist.

References


